Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 3/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.45 |
| ▸ | FABP7 | O15540 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30001711 | 0.91 | KMT2A (0.53) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL17003708 | 0.91 | KMT2A (0.53) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL27333025 | 0.90 | KMT2A (0.52) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL30877996 | 0.90 | KMT2A (0.52) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL26518049 | 0.87 | KMT2A (0.53) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL12665923 | 0.86 | KMT2A (0.62) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL23882966 | 0.85 | CASP3 (0.50) | KMT2AEPHX2CASP3 | |
| SCHEMBL30001661 | 0.85 | CASP3 (0.50) | KMT2AEPHX2CASP3 | |
| SCHEMBL23882965 | 0.85 | CASP3 (0.50) | KMT2AEPHX2CASP3 | |
| SCHEMBL27443207 | 0.85 | KMT2A (0.49) | KMT2AEPHX2CASP3FABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099897-A1 | NOVEL LINKERS AND ITS PREPARATION METHODS THEREOF | ZYDUS LIFESCIENCES LIMITED (IN) | 2026-05-15 | — | — | WO | disclosed |
| US-11845934-B2 | Specific synthetic chimeric xenonucleic acid guide RNA; s(XNA-gRNA) for enhancing CRISPR mediated genome editing efficiency | DiaCarta Inc. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230295077-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE SIDE CHAIN | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2023-09-21 | — | — | US | disclosed |
| US-20220025453-A1 | XENONUCLEIC ACID-MEDIATED MULTIPLEX QPCR CLAMPING TECHNOLOGY FOR LUNG CANCER MUTATION DETECTION | Sha michael y (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220025437-A1 | NOVEL METHOD OF COMBINED MOLECULAR CLAMPING AND ALLELE SPECIFIC qPCR TECHNOLOGY FOR KRAS G12C MUTATION DETECTION | SUN QING (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220025453-A1 | XENONUCLEIC ACID-MEDIATED MULTIPLEX QPCR CLAMPING TECHNOLOGY FOR LUNG CANCER MUTATION DETECTION | Sha michael y (US) | 2022-01-27 | — | — | US | disclosed |
| US-11208689-B2 | DNA mutation detection employing enrichment of mutant polynucleotide sequences and minimally invasive sampling | DIACARTA LTD | 2021-12-28 | — | — | US | disclosed |
| US-11208689-B2 | DNA mutation detection employing enrichment of mutant polynucleotide sequences and minimally invasive sampling | DIACARTA LTD | 2021-12-28 | — | — | US | disclosed |
| US-20190330692-A1 | DNA MUTATION DETECTION EMPLOYING ENRICHMENT OF MUTANT POLYNUCLEOTIDE SEQUENCES AND MINIMALLY INVASIVE SAMPLING | POWELL MICHAEL J (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190330621-A1 | SPECIFIC SYNTHETIC CHIMERIC XENONUCLEIC ACID GUIDE RNA; s(XNA-gRNA) FOR ENHANCING CRISPR MEDIATED GENOME EDITING EFFICIENCY | POWELL MICHAEL J (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190330692-A1 | DNA MUTATION DETECTION EMPLOYING ENRICHMENT OF MUTANT POLYNUCLEOTIDE SEQUENCES AND MINIMALLY INVASIVE SAMPLING | POWELL MICHAEL J (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190330621-A1 | SPECIFIC SYNTHETIC CHIMERIC XENONUCLEIC ACID GUIDE RNA; s(XNA-gRNA) FOR ENHANCING CRISPR MEDIATED GENOME EDITING EFFICIENCY | POWELL MICHAEL J (US) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330621-A1 | SPECIFIC SYNTHETIC CHIMERIC XENONUCLEIC ACID GUIDE RNA; s(XNA-gRNA) FOR ENHANCING CRISPR MEDIATED GENOME EDITING EFFICIENCY | XPA, CDA, GDA | KMT2A 331/4885EPHX2 3693/4885CASP3 2531/4885 |
| US-11845934-B2 | Specific synthetic chimeric xenonucleic acid guide RNA; s(XNA-gRNA) for enhancing CRISPR mediated genome editing efficiency | XPA, CDA, GDA | KMT2A 331/4885EPHX2 3693/4885CASP3 2531/4885 |
| US-20230295077-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE SIDE CHAIN | GLP1R, GCG, GCGR | KMT2A 3435/4885EPHX2 1604/4885CASP3 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.